Ainos provides mid-year update outlining milestones

Ainos (AIMD) issued a mid-year update outlining key strategic milestones achieved during the first half of 2025. The Company has transitioned from R&D to commercial execution, marked by its first AI Nose-driven revenue, expanded industry partnerships, and regulatory approval for its lead VELDONA human drug candidates to enter clinical trials. These developments position Ainos to launch scaled pilots in 2H 2025 and prepare for commercial rollout in 2026. “The first half of 2025 was an inflection point for Ainos,” said Eddy Tsai, Chairman, President & CEO. “Q1 revenue increased 412% year-over-year, primarily driven by our AI Nose project in Japan’s senior care sector. We’re now operating in real-world settings, turning vision into execution. Japan and Taiwan are ideal proving grounds for AI Nose smelltech due to their demographic pressures and demand for care innovation. Our presence at Computex 2025 catalyzed strong new partnership interest. As we enter scaled pilots across verticals, we are also actively pursuing new strategic collaborations to unlock long-term value.”